Aptamer selection against alpha-defensin human neutrophil peptide 1 on an integrated microfluidic system for diagnosis of periprosthetic joint infections. Issue 2 (16th December 2021)

• Record Type: Journal Article
• Authors: Gandotra, Rishabh; Wu, Hung-Bin; Gopinathan, Priya; Tsai, Yi-Cheng; Kuo, Feng-Chih; Lee, Mel S.; Lee, Gwo-Bin
• Is Part Of: Lab on a chip. Volume 22:Issue 2(2022)
• Page Start: 250
• Page End: 261
• Publication Date: 2021-12-16
• Subjects: Miniature electronic equipment -- Periodicals; Combinatorial chemistry -- Periodicals; Biotechnology -- Periodicals; 543.0813
• DOI: 10.1039/d1lc00969a
• Languages: English
• ISSNs: 1473-0197

Abstract

Abstract : An automated process was carried out on an integrated microfluidic system that featured SELEX 1) a positive + negative + competitive selection on a single chip and 2) aptamer-based ELISA-like assay for detection of PJI positive and negative samples. Abstract : Periprosthetic joint infections (PJIs) arising from joint arthroplasty are dreadful, yet difficult to diagnose in subtle cases. Definite diagnosis requires microbiological culture to confirm the causative pathogens. However, up to 40% of culture-negative PJI needs other surrogate biomarkers such as human neutrophil peptide 1 (HNP 1) to improve diagnostic accuracy or gauge therapeutic responses. To devise a diagnostic method, systematic evolution of ligands by exponential enrichment (SELEX) (five rounds) was used to screen PJI biomarkers on a compact (20 × 20 × 35 cm), integrated microfluidic system equipped with two separate Peltier devices and one magnetic control module where an aptamer with high affinity and specificity for HNP 1, which has been used as one of the synovial fluid (SF) biomarkers for detecting PJI, was identified for the first time. Two rounds of negative selection (with immunoglobulin G & human serum album) on-chip followed by one round of unique "competitive selection" with SF extracted from PJI patients validated the specificity of the HNP 1 aptamer. The dissociation constant was measured to be 19 nM. The applicability of SF HNP 1 levels for diagnosing PJI was then verified by a new aptamer-based enzyme-linked immunosorbent assay (ELISA)-like assay. It is envisioned that this new aptamer and the associated assay could be used in future clinical applications.